Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 4NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Squamous Cell Carcinoma of Head and Neck 3Recurrent Squamous Cell Lung Carcinoma 3Prostatic Neoplasms 2Colorectal Neoplasms 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Non-small Cell Lung Cancer 1Solid Malignancies 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Lung Cancer Metastatic 1Esophageal Neoplasms 1Colorectal Cancer Metastatic 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1Advanced Rare Tumours 1

Interventions

Oxaliplatin 21Fluorouracil 20Leucovorin 19Capecitabine 18Irinotecan 13Radiotherapy 8Bevacizumab 7Cetuximab 6Folfox protocol 4cediranib 2Radiation 2Psychiatric Rehabilitation 2Octreotide 2Cisplatin 2Chemoradiotherapy 2tipifarnib 1pertuzumab 1olaparib 1mercaptoundecahydrododecaborate 1eniluracil 1durvalumab 1brivanib 1alpha-Tocopherol 1Watchful Waiting 1Vitamin E 1Trastuzumab 1Tegafur 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Standard of Care 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Rectal Neoplasms × durvalumab × Clear all
NCT03102047 2022-04-20

Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer

NSABP Foundation Inc

Phase 2 Completed
45 enrolled
Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡